We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Artificial Light Stimulates Cancer Growth

By Biotechdaily staff writers
Posted on 29 Dec 2005
A study of laboratory mice has shown that exposure to artificial light at night stimulated the growth of human breast tumors by suppressing the levels of melatonin.

In contrast, extended periods of darkness at night greatly slowed the growth of the tumors. More...
These results help explain why women who work night shifts have a higher rate of breast cancer than other women. In advanced industrial countries such as the United States, it provides a new explanation for the epidemic rise in breast cancer incidence. The study findings were reported in the December 1, 2005, issue of Cancer Research.

"We know that many tumors are largely dependent on a nutrient called linoleic acid, an essential fatty acid, in order to grow,” observed lead author David Blask, M.D., Ph.D., a neuroendocrinologist with the Bassett Research Institute (Cooperstown, NY, USA). "Melatonin interferes with the tumor's ability to use linoleic acid as a growth signal, which causes tumor metabolism and growth activity to shut down.

To test this hypothesis, the researchers injected human breast cancer cells into laboratory mice. After these cells developed into cancerous tumors, the tumors were implanted into female rats where they could continue to grow. The researchers took blood samples from 12 healthy volunteers under three different conditions: during the daytime, during the night following two hours of complete darkness, and during the night following 90 minutes of exposure to bright fluorescent light. These blood samples were then pumped directly through the developing tumors.

"The melatonin-rich blood collected from subjects while in total darkness severely slowed the growth of tumors,” said Dr. Blask. "These results are due to a direct effect of the melatonin on the cancer cells. The melatonin is clearly suppressing tumor development and growth.”

In contrast, tests with the melatonin-depleted blood from light-exposed subjects stimulated tumor growth. "We observed rapid growth comparable to that seen with administration of daytime blood samples, when tumor activity is particularly high,” Dr. Blask explained.

Melatonin exerts a strong influence on the body's circadian rhythm, according to the researchers. The disruption of the circadian clock is associated with cancer in humans, and interference with that internal timekeeping can effect a change in favor of tumor development. These results may lead to more artificial lighting and perhaps the use of lighting that has a wavelength and intensity that do not disrupt melatonin levels and internal timekeeping.

"Day workers who spend their time indoors would benefit from lighting that better mimics sunlight,” added Dr. Blask. "Companies that employ shift workers could introduce lighting that allows the workers to see without disrupting their circadian and melatonin rhythms.”




Related Links:
Bassett Hospital

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.